Discounted Cash Flow (DCF) Analysis Levered
Aytu BioPharma, Inc. (AYTU)
$1.67
-0.02 (-1.18%)
All numbers are in Millions, Currency in USD
Free Cash Flow
Year A/P | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Actual | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
| Revenue | 3.66 | 7.32 | 27.63 | 65.63 | 96.67 | 232.56 | 559.47 | 1,345.94 | 3,237.95 | 7,789.60 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (%) | ||||||||||
| Operating Cash Flow | -15.94 | -13.83 | -28.37 | -25.96 | -28.82 | -370.48 | -891.28 | -2,144.16 | -5,158.26 | -12,409.35 |
| Operating Cash Flow (%) | ||||||||||
| Capital Expenditure | -0.07 | -0.06 | -0.39 | -0.94 | -1.38 | -3.32 | -8 | -19.24 | -46.28 | -111.34 |
| Capital Expenditure (%) | ||||||||||
| Free Cash Flow | -16.02 | -13.89 | -28.77 | -26.90 | -30.20 | -373.81 | -899.27 | -2,163.40 | -5,204.54 | -12,520.69 |
Weighted Average Cost Of Capital
| Share price | $ 1.67 |
|---|---|
| Beta | -0.403 |
| Diluted Shares Outstanding | 1.47 |
| Cost of Debt | |
| Tax Rate | 0.10 |
| After-tax Cost of Debt | 5.00% |
| Risk-Free Rate | |
| Market Risk Premium | |
| Cost of Equity | 1.734 |
| Total Debt | 18.19 |
| Total Equity | 2.45 |
| Total Capital | 20.64 |
| Debt Weighting | 88.11 |
| Equity Weighting | 11.89 |
| Wacc |
Build Up Free Cash Flow
Year A/P | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Actual | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
| Revenue | 3.66 | 7.32 | 27.63 | 65.63 | 96.67 | 232.56 | 559.47 | 1,345.94 | 3,237.95 | 7,789.60 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -15.94 | -13.83 | -28.37 | -25.96 | -28.82 | -370.48 | -891.28 | -2,144.16 | -5,158.26 | -12,409.35 |
| Capital Expenditure | -0.07 | -0.06 | -0.39 | -0.94 | -1.38 | -3.32 | -8 | -19.24 | -46.28 | -111.34 |
| Free Cash Flow | -16.02 | -13.89 | -28.77 | -26.90 | -30.20 | -373.81 | -899.27 | -2,163.40 | -5,204.54 | -12,520.69 |
| WACC | ||||||||||
| PV LFCF | -357.33 | -821.76 | -1,889.81 | -4,346 | -9,994.53 | |||||
| SUM PV LFCF | -17,409.43 |
Terminal Value
| Growth in perpetuity method: | |
|---|---|
| Long-term growth rate | |
| WACC (%) | 4.61 |
| Free cash flow (t + 1) | -12,771.10 |
| Terminal Value | -489,314.36 |
| Present Value of Terminal Value | -390,590.75 |
Intrinsic Value
| Enterprise Value | -408,000.18 |
|---|---|
| Net Debt | -1.17 |
| Equity Value | -407,999 |
| Shares Outstanding | 1.47 |
| Equity Value Per Share | -277,573.95 |